| Drug General Information |
| Drug ID |
D0M8CO
|
| Former ID |
DNC004282
|
| Drug Name |
1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H13N3O2
|
| Canonical SMILES |
C1=CC=NC(=C1)NC(=O)NC2=CC=CC3=C2C=C(C=C3)O
|
| InChI |
1S/C16H13N3O2/c20-12-8-7-11-4-3-5-14(13(11)10-12)18-16(21)19-15-6-1-2-9-17-15/h1-10,20H,(H2,17,18,19,21)
|
| InChIKey |
PLKPAJOIRNQZMG-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cell division protein kinase 4 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Cell cycle
|
|
p53 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Tight junction
|
|
T cell receptor signaling pathway
|
|
Hepatitis B
|
|
Measles
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Pancreatic cancer
|
|
Glioma
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Validated targets of C-MYC transcriptional activation
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Oxidative Stress Induced Senescence
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
Oncogene Induced Senescence
|
|
RMTs methylate histone arginines
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Ubiquitin-dependent degradation of Cyclin D1
|
|
Cyclin D associated events in G1
|
|
Meiotic recombination
|
|
WikiPathways
|
DNA Damage Response
|
|
G1 to S cell cycle control
|
|
Ovarian Infertility Genes
|
|
PPAR Alpha Pathway
|
|
Bladder Cancer
|
|
S Phase
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Meiotic Recombination
|
|
Retinoblastoma (RB) in Cancer
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Mitotic G1-G1/S phases
|
|
Cell Cycle
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | J Med Chem. 2001 Dec 20;44(26):4615-27.Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. |
|---|
